Dilantin and Pulmonary mass - a phase IV clinical study of FDA data

Summary:

Pulmonary mass is reported as a side effect among people who take Dilantin (phenytoin sodium), especially for people who are female, 50-59 old, also take Albuterol, and have Convulsion.

The phase IV clinical study analyzes which people have Pulmonary mass when taking Dilantin. It is created by eHealthMe based on reports of 19,857 people who have side effects when taking Dilantin from the FDA, and is updated regularly.

What is Dilantin?

Dilantin has active ingredients of phenytoin sodium. It is often used in epilepsy. eHealthMe is studying from 20,859 Dilantin users. Check the latest studies of Dilantin.

What is Pulmonary mass?

Pulmonary mass is found to be associated with 1,135 drugs and 921 conditions by eHealthMe. Check the latest studies of Pulmonary mass.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

19,857 people reported to have side effects when taking Dilantin.
Among them, 12 people (0.06%) have Pulmonary mass.

Among these 12 people:

What is the gender of people who have Pulmonary mass when taking Dilantin? *

female: 75 %
male: 25 %

What is the age of people who have Pulmonary mass when taking Dilantin? *

What are other drugs people take besides Dilantin? *

What are other side effects people have besides Pulmonary mass? *

Thrombocytopenia (decrease of platelets in blood): 8 people, 66.67%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 5 people, 41.67%
Pulmonary Embolism (blockage of the main artery of the lung): 4 people, 33.33%
Haemoglobin Decreased: 4 people, 33.33%
Haematocrit Decreased: 4 people, 33.33%
Pneumonia: 4 people, 33.33%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 4 people, 33.33%
Red Blood Cell Count Decreased: 4 people, 33.33%
White Blood Cell Count Increased: 3 people, 25.00%
Hypotension (abnormally low blood pressure): 3 people, 25.00%

What are the existing conditions these people have? *

Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 4 people, 33.33%
Skin Blushing/flushing (a sudden reddening of the face, neck): 1 person, 8.33%
Renal Disorder (kidney disease): 1 person, 8.33%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 8.33%
Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 1 person, 8.33%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 1 person, 8.33%
Ingrowing Nail: 1 person, 8.33%
High Blood Pressure: 1 person, 8.33%
High Blood Cholesterol: 1 person, 8.33%
Heart Rate Irregular: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Dilantin and have Pulmonary mass?

- Check whether Pulmonary mass is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dilantin:

Dilantin (20,859 reports)

Pulmonary mass treatments and more:

Pulmonary mass (17,472 reports)

Browse all side effects of Dilantin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary mass:

Pulmonary mass (1,135 drugs)

Browse all the conditions that are associated with Pulmonary mass:

Pulmonary mass (921 conditions)

Related publications that referenced our studies

Akasaka E, Kayo SJ, Nakano H, Ishii N, Hashimoto T, Sawamura D, "Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis", Case reports in dermatology, 2014 Jan .
Akasaka E, Kayo SJ, Nakano H, Ishii N, Hashimoto T, Sawamura D, "Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis", Case reports in dermatology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on phenytoin sodium (the active ingredients of Dilantin) and Dilantin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.